Marquette Asset Management LLC Invests $601,000 in OraSure Technologies, Inc. $OSUR

Marquette Asset Management LLC bought a new position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) in the second quarter, Holdings Channel reports. The institutional investor bought 134,656 shares of the medical instruments supplier’s stock, valued at approximately $601,000.

Several other institutional investors have also recently added to or reduced their stakes in OSUR. Millennium Management LLC boosted its position in OraSure Technologies by 71.1% in the third quarter. Millennium Management LLC now owns 2,112,507 shares of the medical instruments supplier’s stock valued at $6,781,000 after buying an additional 878,151 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of OraSure Technologies by 6.4% during the second quarter. Geode Capital Management LLC now owns 1,869,868 shares of the medical instruments supplier’s stock worth $5,611,000 after buying an additional 112,851 shares in the last quarter. Cannell Capital LLC increased its holdings in shares of OraSure Technologies by 33.7% during the second quarter. Cannell Capital LLC now owns 1,864,989 shares of the medical instruments supplier’s stock worth $5,595,000 after buying an additional 470,536 shares in the last quarter. Kotler Kevin bought a new position in shares of OraSure Technologies in the fourth quarter valued at approximately $4,359,000. Finally, Bridgeway Capital Management LLC raised its stake in shares of OraSure Technologies by 9.5% in the second quarter. Bridgeway Capital Management LLC now owns 1,790,260 shares of the medical instruments supplier’s stock valued at $5,371,000 after acquiring an additional 154,985 shares during the last quarter. 93.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on OSUR. Wall Street Zen raised OraSure Technologies from a “sell” rating to a “hold” rating in a report on Monday. Weiss Ratings upgraded OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $3.00.

Insider Buying and Selling

In other news, Director Steven Kyle Boyd acquired 25,000 shares of the firm’s stock in a transaction on Thursday, May 14th. The shares were purchased at an average cost of $2.99 per share, for a total transaction of $74,750.00. Following the transaction, the director owned 113,462 shares of the company’s stock, valued at approximately $339,251.38. This represents a 28.26% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 4.70% of the company’s stock.

OraSure Technologies Price Performance

OSUR opened at $4.00 on Tuesday. The stock has a market capitalization of $275.40 million, a P/E ratio of -5.80 and a beta of 1.00. The company’s 50 day simple moving average is $4.16 and its 200-day simple moving average is $3.44. OraSure Technologies, Inc. has a one year low of $2.08 and a one year high of $4.58.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.